Randomized clinical trial with alpha 2b-interferon in 26 stage A untreated B-chronic lymphocytic leukemia patients.
In a previous study we obtained a 50% response rate with alpha 2b Interferon in the first stages of chronic lymphocytic leukaemia. We have performed a second study randomizing 34 stage A patients, who were receiving no other treatment (8 non-treated controls and 26 patients who had been treated with 3 modalities). We obtained 17 responses (67%) with one complete haematological response (4%), 9 incomplete (34%) and 7 minor (37%). No bone marrow changes were noted after this treatment but there was a decrease in the lymph nodes or the spleen seen on three occasions. In a new randomised study we have studied the effects of the small doses of Interferon associated with chemotherapy.
Boussiotis
V A
VA
1st Department of Internal Medicine, University of Athens School of Medicine, Greece.
Pangalis
G A
GA
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011897:Random Allocation; D011994:Recombinant Proteins; D012074:Remission Induction
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins